

HUMAN RECOMBINANT DECAY-ACCELERATING FACTOR (DAF) INCREASES SURVIVAL AND LIMITS TISSUE INJURY AFTER HEMORRHAGIC SHOCK.

J.J. Dalle Lucca*, M.O. Simovic, Y. Li, Y. Wang, C. Moratz, F. Pearce
Walter Reed Army Institute of Research
Silver Springs, MD, 20910

G. C. Tsokos
Harvard Medical School
Boston, MA, 02115

ABSTRACT

The current wars in Iraq and Afghanistan have resulted in the highest rates of combat casualties experienced by the U.S. military since the Vietnam conflict, and hemorrhage has been indentified as the principal cause of death among potentially salvageable patients. Hemorrhagic blood loss or resuscitation following hemorrhage leads to complement activation, which in turn, plays a key role in the pathogenesis of subsequent shock, tissue inflammation and multiple organ failure. The current study used a porcine model of controlled hemorrhage to determine the effects of early bolus injection of a complement inhibitor, decay-accelerating factor (DAF), administered 20 minutes after the onset of hemorrhagic shock. We report that hemorrhaged animals if untreated die 100 minutes before the procedure endpoint, whereas animals treated with DAF alone or in combination with resuscitation fluids displayed increased survival when compared to controls. Administration of DAF (5 and 25µg/kg) reduces the volume of Hextend required 60 minutes after achieving target blood pressure by approximately 56.9 and 62%, respectively. Furthermore, DAF-treated pigs showed improvement of hemodynamic and metabolic parameters and reduced injury in several organs including the lungs and the intestine. In summary, our data demonstrate that administration of DAF within 20 minutes of hemorrhagic shock may reduce mortality and morbidity of severely injured soldiers. Furthermore, its effect in reducing or eliminating the need for resuscitation fluids should reflect in great logistical and operational improvement during far-forward medical support missions.

1. INTRODUCTION

Hemorrhage and complications after resuscitation are the major cause of mortality and morbidity associated with battlefield wounds. Associated morbidity includes sepsis, ischemia and reperfusion injury, multiple organ failure, and secondary brain and spinal cord injury (Spain, et al., 1999; Yao, et al., 1998; Ummenhofer and Scheidegger, 2002; Soderstrom and Brumback, 1986). Following hemorrhage and/or resuscitation, intestinal injury and the initiation of an inflammatory response play a major role in the complications that ensue. These complications and secondary organ injury following hemorrhage are associated with the redistribution of blood flow away from less vital organs. Following hemorrhage and resuscitation, the microvascular beds in the intestine and lungs are particularly susceptible to injury. The initiation of an inflammatory response appears to play a major role in the complications that occur subsequent to hemorrhage and resuscitation. We and others have previously demonstrated in rodents that complement activation is centrally involved in causing organ injury following hemorrhage and resuscitation (Yao, et al., 1998; Szebeni, et al, 2003; personal communication). In this study we have used recombinant human decay-accelerating factor (DAF) to inhibit complement activation and demonstrated its beneficial effects in a porcine model of tissue injury induced by hemorrhage and resuscitation.

1.1 Hemorrhage as a Cause of Morbidity and Mortality. The current wars in Iraq and Afghanistan have resulted in the highest rates of combat casualties experienced by the U.S. military since the Vietnam conflict. These casualties suffer wounds that have no common civilian equivalent and more frequently require massive transfusion (greater than 10 units of packed red blood cells in less than 24 hrs) than injured civilians. Military surgeons have found that traditional approaches to resuscitation, particularly in terms of the ratio of blood

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE DEC 2008		2. REPORT TYPE N/A		3. DATES COVERED -	
4. TITLE AND SUBTITLE Human Recombinant Decay-Accelerating Factor (Daf) Increases Survival And Limits Tissue Injury After Hemorrhagic Shoc				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Walter Reed Army Institute of Research Silver Springs, MD, 20910				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited					
13. SUPPLEMENTARY NOTES See also ADM002187. Proceedings of the Army Science Conference (26th) Held in Orlando, Florida on 1-4 December 2008, The original document contains color images.					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 8	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			

products to each other and the timing of these products, often fail to effectively treat the coagulopathy that is invariably present on arrival in these soldiers. This observation has been concurrently noted in the civilian trauma literature and has ignited strong interest in an alternative approach to the resuscitation of these most grievously injured patients. These approaches include among others the use of permissive hypotension, the prevention and aggressive treatment of hypothermia, and introduction of new alternatives to fluid infusion resuscitation. This strategy has been called "damage control resuscitation" to emphasize its pairing with damage control surgical techniques (Beekley, 2008).

1.2 Complement (C) activation in hemorrhage. DAF, a ubiquitously expressed intrinsic C regulatory protein, inhibits C activation by interfering with the function of C3/C5 convertases in both of classic and alternative pathways, thereby limiting local C3a/C5a and C5b-9 (MAC) production (Lublin and Atkinson, 1989; Miwa and Song, 2001). In the present study, we investigated potential effects of DAF on resuscitation fluid requirement, hemodynamic responsiveness, tissue damage, and animal survivability after hemorrhagic shock managed with a hypotensive resuscitation strategy.

We have previously demonstrated that C inhibition with DAF results in tissue protection during ischemia/reperfusion in mice (Weeks, et al., 2007). We have also reported previously that bolus injection of antibody against C5 results in significant decrease in resuscitative fluid requirements after hemorrhagic shock in rats (Peckham, et al., 2007). In continuing our efforts to identify the most efficacious C inhibitor to limit tissue injury and minimize resuscitation fluid volumes we investigated the effect of DAF administered 20 minutes after the onset of hemorrhagic shock in a porcine model of hemorrhage/resuscitation. We report that indeed DAF, a human recombinant protein, limits the resuscitation fluid volumes and prevents significantly tissue injury.

2. MATERIALS AND METHODS

The study adhered to the principles stated in the Guide for the care and use of Laboratory Animals was approved by the Institute's Animal Care and Use Committee and was performed in a facility accredited by the Association for

Assessment and Accreditation of Laboratory Animal Care, International. All research was conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations related to animals and experiments involved animals.

2.1 Reagents and antibody: Recombinant human CD55/DAF was obtained from R&D Systems (Minneapolis, MN). 6% Hetastarch in lactated electrolyte injection (Hextend®) was from Hospira Inc. (Berkeley, CA). Polyclonal anti-serum to human C5 antibody was purchased from Quidel Corporation (San Diego, CA).

2.2 Experimental design. The animals were hemorrhaged using controlled, isobaric Wiggers' model of controlled hemorrhagic shock (Figure




Figure 1. Scheme of the experimental design in pigs. Actual and target mean arterial blood pressure (MAP) are shown as are volume of shed blood and Hextend infused.

1). The animals (swine, Yorkshire crossbred, 12 weeks old, 30-40 kg) were enrolled in one of seven experimental groups: 1) H, hemorrhage only (n = 9); 2) H + Hex, hemorrhage + Hextend® (n = 9); 3) H + DAF50µg, hemorrhage + DAF (50µg/kg bw, n = 8); 4) H + DAF5µg+Hex, hemorrhage + DAF (5µg/kg bw)+Hextend® (n=4); 5) H + DAF25µg + Hex, hemorrhage + DAF (25µg/kg bw) + Hextend® (n=6); 6) H+DAF50µg + Hex, hemorrhage + DAF (50µg/kg bw) + Hextend® (n=6); and 7) Control, Sham (not hemorrhaged, n = 5). Animals were hemorrhaged to a MAP of 35mmHg over a period of 15 minutes and then held at 35mmHg for 20 minutes. At the end of 20-minute stabilization period animals underwent resuscitation with Hextend® to a target MAP of 70 mmHg over 15 minutes and maintained with a minimum MAP of 70 mmHg for 180 minutes. Recombinant human DAF was given as bolus in 60 ml of saline simultaneously with the start of resuscitation. Arterial blood samples were obtained at the prior to surgery (Pre-Op), prior to hemorrhage (C1, C2), hemorrhage to 35 mmHg (35 mmHg) of MAP, prior to resuscitation, at 70 mmHg of MAP, and then at 20 minute intervals throughout the experimental protocol. Blood samples were

analyzed for complement activation, hematocrit, PO₂, PCO₂, pH, HCO₃, glucose, lactate, Na⁺, K⁺, Ca⁺⁺, Cl⁻.

2.3 Tissue harvest: The animals were euthanized by lethal bleeding and isoflurane at endpoint. Tissue samples including lung and small intestine were removed, frozen in liquid nitrogen and stored at -80°C for gene and protein expression, or fixed with 10% formalin or 4% paraformaldehyde for histological and immunohistochemical analysis.

2.4 Tissue protein extraction: Frozen tissue samples were thawed, washed with ice-cold PBS, suspended in RIPA buffer containing protease inhibitors (2µg/ml of aprotinin, 10µM of leupeptin, 1mM of AEBSF), and minced on ice. Then, the samples were sonicated on ice at setting 5, for 4 x 10s at continuous output, with 10s pause in between. The samples were then centrifuged at 13,000 rpm for 10min at 4°C. The supernatants were frozen and stored at -80°C until further processing. Aliquots were used to determine protein concentration.

2.5 Histological examination: 10% formalin-fixed tissues were embedded in paraffin, sectioned and stained with hematoxylin-eosin (H&E). Histological evaluation was observed and histological images were recorded under a light microscope (Olympus Leica, AX80,) with ×40/×20 objective by a pathologist blind to the treatment groups. Histological injury scores were graded using the scales as follow:

For lung injury scoring as described previously (Carraway, et al., 2003), four parameters (alveolar fibrin edema, alveolar hemorrhage, septal thickening and intra-alveolar inflammatory cells) were scored on each slide for 1) severity (0: absent; 1, 2 and 3 for more severe changes) and 2) extent of injury (0: absent; 1: <25%; 2: 25-50%; 3: >50%). for the injury score represents the sum of the extent and the severity of injury.

Mucosal damage of small intestine for each slide was graded on the six-tiered scale (Fleming, et al., 2002; Rehrig, et al., 2001). A score of 0 was assigned to a normal villus; villi with tip distortion were scored as 1; villi lacking goblet cells and containing Gugenheims' spaces were score as 2; villi with patch disruption of the epithelial cells were scored as 3; villi with exposed but intact lamina propria and epithelial

cell sloughing were assigned a score of 4; villi in which the lamina propria was exuding were scored as 5; villi displaying hemorrhage or denuded were scored as 6.

2.5 Statistical analysis: Data are expressed as Mean ± SEM. The logrank test or one- or two-way ANOVA. P values <0.05 were considered significant.

3. RESULTS

3.1 Baseline characteristics. The experimental groups did not differ significantly in the baseline characteristics including weight, hemoglobin concentration, arterial pH, pO₂, pCO₂, glucose, HCO₃, base excess, potassium, ionized calcium, lactate levels, and MAP. The groups of animals did not differ in the total blood loss during the 35-mmHg ceiling hemorrhagic phase (data not shown).

3.2 Hemodynamic and metabolic changes. At the end of the 35-mmHg ceiling hemorrhage phase ("Decompensation"), mean arterial pressure (MAP) in treated animals except those in the Hemorrhage + DAF25µg + Hextend® group was not different from that in the Hemorrhage group. There were no clear differences in shock index, arterial pH, pCO₂, HCO₃, base excess, lactate, glucose, potassium, or ionized calcium levels between treated and non-treated hemorrhage at the decompensation point. Mean arterial pressure (MAP) in animals treated with the combination of DAF and Hextend® was significantly higher at 120 min from the onset of resuscitation when compared with non-treated hemorrhaged animals or those treated only with a high dose of DAF (Table 1). The administration of a high dose of DAF (50µg/kg b.w.) without Hextend® did not clearly increase the mean blood pressure throughout the observation. Shock index, that is, the ratio of heart rate to systolic blood pressure, in hemorrhaged animals treated with the combination of DAF and Hextend® was significantly lower than in non-treated animals. The high dose of DAF alone also significantly decreased shock index in hemorrhaged animals at 120 min from the onset of resuscitation phase (Table 1). Shock index in animals treated with

Table 1. Effects of DAF on hemodynamics and metabolism in pigs during hemorrhagic shock

		Treatment					
		Hemorrhage (H)	H+Hex	H+DAF5µg+Hex	H+DAF25µg+Hex	H+DAF50µg+Hex	H+DAF50µg
MAP (mm Hg)	Decomp. 120 min	29.41±3.60 29.58±2.48	33.74±0.58 68.53±5.82***‡	35.64±1.57 68.84±0.99***‡	35.44±0.94*** 71.06±1.75***‡	35.09±0.87 69.69±0.50***‡	35.39±1.14 43.16±3.46
Shock Index	Decomp. 120 min	2.47±0.20 4.48	2.69±0.27 1.26±0.11***‡	3.00±0.59 1.41±0.06***‡	2.16±0.22 1.44±0.13***‡	2.20±.24 1.31±0.05***‡	2.34±0.17 2.49±0.35***
pH	Decomp. 120 min	7.36±0.06 7.13±0.12	7.42±0.01 7.43±0.03**	7.43±0.05 7.50±0.01***	7.37±0.03 7.45±0.02***	7.41±0.02 7.50±0.02***	7.36±0.02 7.40±0.04**
pCO ₂ (mm Hg)	Decomp. 120 min	59.54±11.88 62.30±12.48	50.05±2.61 45.56±0.75	45.71±5.22 41.56±1.05*	47.21±2.32 42.84±1.75*	46.11±3.51 38.28±1.85*	56.56±2.67 55.35±6.05
HCO ₃ (mmol/L)	Decomp. 120 min	31.06±1.39 28.83±2.48	32.03±0.94 30.54±1.46	29.38±0.71 32.54±0.56	27.82±1.64 30.48±1.66	29.04±0.85 29.43±0.51	31.72±0.80 33.21±0.83
Base Excess (mmol/L)	Decomp. 120 min	32.50±1.33 30.50±3.00	33.67±0.97 32.00±1.35***	30.63±0.83 33.88±0.69***	28.93±1.47 31.25±1.56***	30.36±0.94 30.39±0.56***	33.31±0.82 34.81±0.87***
Lactate (mmol/L)	Decomp. 120 min	2.81±0.53 6.75±1.28	2.32±0.43 2.67±1.26**	3.88±1.07 1.99±0.31***	3.74±1.07 2.64±1.13***	2.27±0.21 1.71±0.33***	2.12±0.34 2.24±0.50***
Glucose (mg/dl)	Decomp. 120 min	126.33±23.26 58±38	112.33±16.55 93.88±8.73	141.75±3.25 103.25±4.13	173±30.59 122.8±13.42	122±6.38 92.67±6.98	115.38±15.89 99.5±24.48
Potassium (mmol/L)	Decomp. 120 min	5.37± 0.53 5.8± 2	4.57±0.12 4.34±0.37*‡	4.63±0.31 3.93±0.11***‡	4.83±0.23 4.66±0.09†	4.74±0.11 4.13±0.27***‡	4.6± 0.08 5.5±0.53
Ionized Calcium (mmol/L)	Decomp. 120 min	1.24±0.04 1.16±0.02	1.21±0.04 1.14±0.03	1.11±0.02 0.95±0.05	1.32±0.02 1.28±0.02‡	1.21±0.02 1.15±0.04	1.20±0.02 1.16±0.06‡

n =3-9. Decomp.=decompensation; decompensatory shock. 120 min refers to the time after the onset of infusion. Two-way ANOVA (Bonferroni post tests) was performed. *p < 0.05 vs. H; **p < 0.01 vs. H; ***p < 0.001 vs. H; † p < 0.05 vs. H+DAF50µg; ‡p < 0.01 vs. H + DAF50µg; ¶p < 0.001 vs. H + DAF50µg; # p < 0.01 vs. H+DAF5µg+Hex; § = p < 0.001 vs. H+DAF5µg+Hex.

DAF alone was not different from the index in not-treated hemorrhage (data not shown). Treatment with DAF and/or Hextend® corrected pH levels in hemorrhaged animals at 120 min from the onset of resuscitation. Only the combination of DAF and fluid though reduced pCO₂ in hemorrhaged animals. There were no clear changes in bicarbonate levels between the experimental groups at 120 min (Table 1). Significantly reduced bicarbonate levels and base deficit were observed in the H + DAF25µg + Hextend® group at the resuscitation point of the target MAP. Treatment with DAF alone or followed by fluid infusion significantly improved base deficit in hemorrhage. There were no differences in potassium or ionized calcium concentration between hemorrhaged non-treated animals and those treated with DAF50µg (Table 1). The observed differences in electrolyte concentrations between the Hemorrhage group and animals treated with combined agents may be attributed to diluted blood plasma by infused Hextend®, a plasma expander.

3.3 Fluid requirements. To determine whether treatment with DAF reduces requirement of resuscitation fluid, we calculated the ratio of cumulative fluid infusion over total

blood loss (TBL) for each group at 20, 80, 140 and 200 minutes after resuscitation with Hextend® (Figure 2). The combination of smaller doses of DAF (5, 25µg/kg b.w., i.v.) followed by infusion of Hextend® significantly reduced the requirement for resuscitative fluid at 60 min after target blood pressure was achieved (70 mmHg) when compared with the animals treated with Hextend® alone (p<0.05). DAF (25µg/kg) in combination with Hextend® significantly reduced the fluid requirement at 1 and 2 hours after the target point of resuscitation when compared animals treated at higher dose of DAF (50 µg/kg) plus Hextend® (Figure 2).

3.4 DAF prolongs animal survival. To determine whether DAF increases survival of hemorrhaged animals, we monitored animal mortality and cumulative survival was plotted (Figure 3). Administration of Hextend® with or without DAF increased animal survival (p<0.01). Superior survival rates were observed in animals treated with a high dose of DAF (50µg/kg b.w.) when compared with those treated with only Hextend® (p<0.05) alone or in combination with DAF.

3.5 DAF limits lung injury associated with hemorrhage and resuscitation. H&E




Figure 2. DAF treatment reduces fluid requirement in a swine hemorrhagic model managed with hypotensive resuscitation. The ratio of cumulative fluid infusion over total blood loss (TBL) was calculated for each group at 20, 80, 140 and 200 minutes after Hextend resuscitation. The number of animals are given on the bars. * $P < 0.05$; ** $P < 0.01$ (two-way ANOVA; Bonferroni post tests).

stained histological sections (Figure 4A) and injury scores (Figure 4B) showed marked lung injury after hemorrhage and/or resuscitation. Histopathological analysis of lung tissues revealed destruction of the alveolar architecture with severe alveolar hemorrhage and moderate inflammation compared with Sham operated. Treatment with DAF alone resulted in optimal reduction in tissue damage when compared to all other groups. Significant lung tissue protection was also observed in animals treated with DAF (5 μ g/kg b.w.) plus Hextend when compared to Hextend alone or Hemorrhage alone.

3.6 DAF limits intestinal injury associated with hemorrhage and resuscitation. Histological changes (Figure 5A) and injury scores (Figure 5B) of small intestines from the

same animals as described above were examined. When compared with small intestines obtained from Sham pigs, intestines obtained from pigs subjected to hemorrhage or hemorrhaged and resuscitation exhibited epithelial cell sloughing, villi denuding, necrosis and inflammation, whereas animals treated with DAF (50 μ g/kg) alone or DAF (5 μ g/kg) plus Hextend® showed significantly reduction in intestinal injury (Figure 5B). When higher dose of DAF (50 μ g/kg-bw) was used in combination with Hextend® it resulted in augmented hemorrhage-induced intestinal damages compared with that of lower dose DAF (5 μ g/kg) followed by resuscitation.

3.7 Effect of DAF in C5a deposition in animal lungs. To understand whether DAF exerts its major molecular function in complement inhibition, we detected the expression of C5a in lungs from the animals by immunoblot analysis (Figure 6A and 6B). Increased amounts of C5a were found in lungs from animals undergoing hemorrhage and hemorrhage followed by resuscitation compared with Sham animals ($p < 0.001$). Treatment though with DAF either at a dose of 50 μ g/kg in hemorrhaged animals or a dose of 5 μ g/kg in the animals with hemorrhage plus resuscitation limited significantly the amounts of C5a in the lungs ($p < 0.05$).




Figure 3. Treatments with DAF and/or Hextend® clearly increased survival of hemorrhaged animals. Pigs were subjected to the protocol and randomized in a blinded fashion. Mortality was monitored and cumulative survival was plotted and logrank test was applied ($p < 0.05$). H + DAF50 μ g vs. H + Hex, $P < 0.05$; H + DAF50 μ g vs. H + DAF50 μ g + Hex, $P < 0.05$; H vs H+DAF50 μ g, $p < 0.0001$; H vs H+DAF50 μ g+Hex, $p < 0.01$; H vs H+DAF25 μ g+Hex, $p < 0.01$; H vs H+DAF50 μ g+Hex, $p < 0.05$; H + Hex vs. H + DAF5, 25 or 50 μ g/kg + Hex, $P > 0.05$; H + DAF50 μ g vs. H + DAF25 μ g + Hex, $P > 0.05$; H + DAF50 μ g vs. H + DAF5 μ g + Hex, $P > 0.05$.




Figure 4. DAF mitigates lung injury in a swine hemorrhagic model. A, Representative H&E stained histological sections of lung from pigs subjected to the protocol. x400. B, lung injury scores were calculated using the scale shown in *Materials and Methods* for each animal. * $p < 0.001$ vs. H, H+Hex and H+DAF50µg+Hex, $p < 0.05$ vs. H+DAF5µg+Hex; † $p < 0.001$ vs. H, H+Hex; ‡ $p < 0.001$ vs. H, $p < 0.05$ vs. H+Hex; # $p < 0.01$ vs. H+DAF5µg+Hex, $p < 0.001$ vs. H+DAF50µg (One-Way ANOVA, Tukey's post test).




Figure 5. DAF attenuates HS-mediated intestinal injury of pigs. A, Representative histological changes of small intestines in the pigs were shown. B, Intestinal injury scores evaluated by a standard shown in *Materials and Methods*. (x200). Group data were compared using one-way ANOVA followed by Tukey's Multiple Comparison Test with p values of < 0.05 considered significant. Tukey: * $p < 0.001$ vs. H, H+Hex and H+DAF50µg+Hex; $p < 0.05$ vs. H+DAF5µg+Hex; † $p < 0.001$ vs. H; $p < 0.05$ vs. H+Hex; ‡ $p < 0.05$ vs. H; # $p < 0.01$ vs. H+DAF5µg+Hex, $p < 0.001$ vs. H+DAF50µg.




Figure 6. DAF reduces C5a deposition in lungs from animals subjected to hemorrhage or hemorrhage plus resuscitation. (A) Extracted proteins from lung tissues were separated in SDS gel, transferred onto PVDF membrane, then immunoblotted with anti-C5a and anti-β-actin antibodies. (B) C5a was quantified by densitometry and the ratio over β-actin was calculated for each sample. * $p < 0.05$, ** $p < 0.01$.

4. DISCUSSION

Hemorrhagic blood loss or resuscitation following hemorrhage leads to complement activation (Yao, et al., 1998; Szebeni, et al, 2003; Peckham, et al., 2007). DAF inhibits the alternative complement pathway by accelerating decay of the convertase enzymes formed by C3b and factor B (Lublin and Atkinson, 1989; Miwa and Song, 2001). Thus, DAF treatment following hemorrhage attenuates complement activation caused by hemorrhage or hemorrhage and resuscitation. Several important findings were observed in the present study. First, treatment with either high dose of DAF (50µg/kg) alone or smaller doses of DAF (5-25µg/kg) followed by Hextend® dramatically increased survival;

second, the presence of DAF in the resuscitation fluids protected animals significantly from tissue damage in multiple organs; third, smaller doses of DAF displayed significant reduction of resuscitation fluid requirements; and, finally, administration of DAF corrected altered hemodynamic and metabolic parameters triggered by hemorrhagic shock.

Hypovolemic resuscitation is the current standard of care and has proved successful in many critical hemorrhagic shock patients. However, growing evidence shows that fluid infusion causes excess fluid extravasation into the interstitial space which may worsen trauma-related complications and can lead to dilutional coagulopathy (Hai, 2004; Moore, et al., 2004; Revell, et al., 2003; Stern, 2001). Starch-containing fluids such as Hextend® may also cause derangements in coagulation and pruritus (Hardy, et al., 2006; Bork, 2005). Therefore strategies aimed at reducing or eliminating the need for resuscitation fluid infusion has been identified as a major requirement for both military and civilian medicine. Another requirement identified by special operations medics as well as tactical combat casualty care experts relates to identification of volume-sparing adjuncts. Specifically, it should reduce the carrying load of medics in forward military environments and with delayed evacuation or mass casualty scenarios where availability of resuscitation fluids may be limited and requires significant logistical footprint. In this study, we report significant reduction of resuscitation fluid requirements with intravenous bolus injection of DAF. The volume sparing effects of DAF are consistent with our previous unpublished data from a rat hemorrhagic model and it suggests that DAF may have the capability to regulate microvascular function.

Although Hextend® alone improves some hemodynamic and metabolic parameters, it also aggravates organ injury. Therefore, the present study provides an attractive candidate to mitigate these side effects of Hextend® by demonstrating the efficacy and safety of bolus injection of DAF as either adjunct therapy or replacement to resuscitation fluid.

The present study also revealed a potential limitation related to the therapeutic range of DAF when combined with Hextend. Animals receiving the highest dose of DAF (50µg/kg b.w.) followed by Hextend® infusion not only failed to show beneficial effects but also masked any positive effects of Hextend® alone.

Further studies will be needed to clarify this outcome. Complement inhibition may interfere with the coagulation cascade (Horstick, et al., 2001; Tassani P, et al., 2001). It is also known that colloidal and starch fluids may also cause dilutional coagulopathy (Kentnera, et al., 2005; Vollmar and Menger, 2004). The increased mortality associated with the administration of high dose of DAF and Hextend may be caused by the induction of severe coagulopathy. We are currently in the process of determining the status of the coagulation cascade in blood samples which were collected from all groups throughout the experiment.

DAF administered at the beginning of resuscitation increases survival, reduces resuscitation requirements, prevents tissue damage and also provides a basis for replacement therapy to hypovolemic resuscitation. All of which has the potential to dramatically reduce medic load and logistic footprint during far-forward medical support to military operations. Furthermore, the effects of DAF in preventing onset of decompensation during early stages of shock poses an attractive therapeutic approach in civilian emergency medical response to trauma such as those observed followed automobile crashes.

In conclusion, the present study reveals for the first time in a military relevant model of hemorrhagic shock that bolus injection of DAF given within the time frame observed for the arrival of the first responder in current military operations may be utilized as an important life saving tool leading to decreased mortality and possibly morbidity of severely injured casualties.

ACKNOWLEDGMENT(S)

The skillful technical assistance of Ms Irene Gist, Mr. Michael J. Falabella, and Mr. Parag Apte, as well as the staff from the Department of Pathology and Department of Veterinary Surgery at Walter Reed Army Institute of Research is gratefully appreciated.

5. REFERENCES

Aragno, M., Cutrin, J.C., Mastrocala, R., Perrelli, M.G., Restivo, F., Poli, G., Danni, O. and Boccuzzi G., 2003: Oxidative Stress and Kidney Dysfunction due to Ischemia / Reperfusion in Rat: Attenuation by Dehydroepiandrosterone, *Kidney Int.*, 64:836-843.

- Beekley, A., 2008: Damage Control Resuscitation: A Sensible Approach to The Exsanguinating Surgical Patient, *Crit. Care Med.*, 36(7), S267-74.
- Bork, K., 2005: Pruritus Precipitated by Hydroxyethyl Starch: A Review, *Br. J. Dermatol.*, 52(1):3-12.
- Carraway, MS., Welty-Wolf KE., Miller, DL., Ortel, TL., Idell, S., Ghio, AJ., Petersen, LC. and Piantadosi, CA., 2003: Blockage of Tissue Factor: Treatment for Organ Injury in Established Sepsis, *American Journal of Respiratory and Critical Care Medicine*, 167:1200-1209.
- Fleming, SD., Shea-Donohue, T., Guthridge, JM., Kulik, L., Waldschmidt, TJ., Gipson, MG., Tsokos, GC. and Holers VM., 2002: Mice Deficient in Complement Receptors 1 and 2 Lack A Tissue Injury-Inducing Subset of The Natural Antibody Repertoire, *J. Immunol.*, 15;169(4):2126-33.
- Hai, SA., 2004: Permissive Hypotensive Resuscitation--An Evolving Concept in Trauma, Permissive Hypotensive Resuscitation--An Evolving Concept in Trauma. *J. Pak. Med. Assoc.*, 54(8):434-6.
- Hardy, JF., de Moerloose, P. and Samama, CM., 2006: Massive Transfusion and Coagulopathy: Pathophysiology and Implications for Clinical Management, *Can. J. Anaesth.*, 53(6 Suppl):S40-58.
- Horstick, G., Berg O., Heimann A., *et al.*, 2001: Application of C1- Esterase Inhibitor during Reperfusion of Ischemic Myocardium. Dose-Related Beneficial versus Detrimental Effects, *Circ.*, 104, 3125-31.
- Kentner, R., Safara, P., Prueckner, S., Behringer, W., Wua, X., Henchira, J., Ruemeline, A, Tisherman, S. 2005: Titrated Hypertonic/Hyperoncotic Solution for Hypotensive Fluid Resuscitation during Uncontrolled Hemorrhagic Shock in Rats, *Resus.*, 65, 87-95.
- Li, K., Sacks, SH. and Zhou, W., 2007: The Relative Importance of Local and Systemic Complement Production in Ischaemia, Transplantation and Other Pathologies, *Molecular Immunology*, 44:3866-3874.
- Lublin, DM. and Atkinson, JP., 1989: Decay-Accelerating Factor: Biochemistry, Molecular Biology, and Function, *Annu. Rev. Immunol.*, 7:35-58.
- Miwa, T., and Song, WC., 2001. Membrane Complement Regulatory Proteins: Insight from Animal Studies and Relevance to Human Diseases. *Int. Immunopharmacol.* 1:445-459.
- Moore, FA., McKinley, BA. and Moore, EE., 2004: The Next Generation in Shock Resuscitation, *Lancet*, 12;363(9425):1988-96.
- Peckham, RM., Handrigan, MT., Bentley TB., Falabella, MJ, Chrovian, AD., Stahl, GL. and Tsokos, GC., 2007: C5-Blocking Antibody Reduces Fluid Requirements and Improves Responsiveness to Fluid Infusion in Hemorrhagic Shock Managed with Hypotensive Resuscitation, *J. Appl. Physiol.*, 102(2):673-80.
- Rehrig, S., Fleming, SD., Anderson, J., Guthridge, JM., Rakstang, J., McQueen, CE., Holers, VM., Tsokos, GC. and Shea-Donohue T., 2001: Complement Inhibitor, Complement Receptor 1-Related Gene/Protein y-Ig Attenuates Intestinal Damage after The Onset of Mesenteric Ischemia/Reperfusion Injury in Mice, *J. Immunol.*, 15;167(10):5921-7.
- Revell, M., Greaves, I. and Porter, K. 2003: Endpoints for Fluid Resuscitation in Hemorrhagic Shock, *J. Trauma*, 54(5 Suppl):S63-7.
- Spain, DA., Fruchterman, TM., Matheson, PJ., Wilson, MA., Martin, AW. and Garrison, RN., 1999: Complement Activation Mediates Intestinal Injury after Resuscitation from Hemorrhagic Shock, *J. Trauma*, 46:224-233.
- Soderstrom, CA. and Brumback, RJ. 1986: Early Care of The Patient with Cervical Spine Injury, *Orthop. Clin. North. Am.*, 17(1):3-13.
- Stern, SA., 2001: Low-Volume Fluid Resuscitation for Presumed Hemorrhagic Shock: Helpful or Harmful?, *Curr. Opin. Crit. Care*, 7(6):422-30.
- Szebeni, J., Baranyi, L., Savay, S., Götze, O., Alving, CR., Bünger, R. and Mongan, PD., 2003: Complement Activation during Hemorrhagic Shock and Resuscitation in Swine, *Shock*, 20(4):347-55.

DISCLAIMER

Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense. Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the *Guide for the Care and Use of Laboratory Animals*, NRC Publication, 1996 edition.